127 related articles for article (PubMed ID: 20660828)
41. On assessing the presence of evaluation-time bias in progression-free survival in randomized trials.
Kay R; Wu J; Wittes J
Pharm Stat; 2011; 10(3):213-7. PubMed ID: 20568099
[TBL] [Abstract][Full Text] [Related]
42. Estimating causal effect with randomized controlled trial.
Shrier I
Epidemiology; 2013 Sep; 24(5):779-81. PubMed ID: 23903885
[No Abstract] [Full Text] [Related]
43. The hazards of endpoints.
Berry DA
J Natl Cancer Inst; 2010 Sep; 102(18):1376-7. PubMed ID: 20826734
[No Abstract] [Full Text] [Related]
44. Critical evaluation of disease stabilization as a measure of activity of systemic therapy: lessons from trials with arms in which patients do not receive active treatment.
Le Tourneau C; Paoletti X; Coquan E; Sablin MP; Zoubir M; Tannock IF
J Clin Oncol; 2014 Jan; 32(3):260-3. PubMed ID: 24297942
[No Abstract] [Full Text] [Related]
45. Compound treatments, transportability, and the structural causal model: the power and simplicity of causal graphs.
Petersen ML
Epidemiology; 2011 May; 22(3):378-81. PubMed ID: 21464653
[No Abstract] [Full Text] [Related]
46. Study Designs for Extending Causal Inferences From a Randomized Trial to a Target Population.
Dahabreh IJ; Haneuse SJA; Robins JM; Robertson SE; Buchanan AL; Stuart EA; Hernán MA
Am J Epidemiol; 2021 Aug; 190(8):1632-1642. PubMed ID: 33324969
[TBL] [Abstract][Full Text] [Related]
47. Principal stratification--a goal or a tool?
Pearl J
Int J Biostat; 2011 Mar; 7(1):20. PubMed ID: 21556288
[TBL] [Abstract][Full Text] [Related]
48. Updates in the treatment of neuroblastoma.
Modak S
Clin Adv Hematol Oncol; 2011 Jan; 9(1):74-6. PubMed ID: 21326151
[No Abstract] [Full Text] [Related]
49. Estimating causal effects using prior information on nontrial treatments.
Bond SJ; White IR
Clin Trials; 2010 Dec; 7(6):664-76. PubMed ID: 20817650
[TBL] [Abstract][Full Text] [Related]
50. Causality in complex interventions.
Rickles D
Med Health Care Philos; 2009 Mar; 12(1):77-90. PubMed ID: 18465202
[TBL] [Abstract][Full Text] [Related]
51. Counterpoint: epidemiology to guide decision-making: moving away from practice-free research.
Hernán MA
Am J Epidemiol; 2015 Nov; 182(10):834-9. PubMed ID: 26507306
[TBL] [Abstract][Full Text] [Related]
52. Tom Ten Have's contributions to causal inference and biostatistics: review and future research directions.
Small DS; Joffe MM; Lynch KG; Roy JA; Russell Localio A
Stat Med; 2014 Sep; 33(20):3421-33. PubMed ID: 23255088
[TBL] [Abstract][Full Text] [Related]
53. Hazards of small clinical trials.
Piantadosi S
J Clin Oncol; 1990 Jan; 8(1):1-3. PubMed ID: 2295901
[No Abstract] [Full Text] [Related]
54. Clinical trials--multiple treatments, multiple end points, and multiple lessons.
Lauer MS; Topol EJ
JAMA; 2003 May; 289(19):2575-7. PubMed ID: 12759328
[No Abstract] [Full Text] [Related]
55. Estimating causal effect with RCTs.
Shrier I
Epidemiology; 2014 Jan; 25(1):162-3. PubMed ID: 24296939
[No Abstract] [Full Text] [Related]
56. Estimating causal effect with RCTs.
Wolfson J
Epidemiology; 2014 Jan; 25(1):162. PubMed ID: 24296938
[No Abstract] [Full Text] [Related]
57. Re: Designing a randomized clinical trial to evaluate personalized medicine: a new approach based on risk prediction.
Simon RM; Freidlin B
J Natl Cancer Inst; 2011 Mar; 103(5):445; author reply 445-6, discussion 446. PubMed ID: 21228315
[No Abstract] [Full Text] [Related]
58. Chemotherapy for neuroblastoma: is it all or none?
Maris JM; Castleberry RP
J Pediatr Hematol Oncol; 2003 Jul; 25(7):512-4. PubMed ID: 12847315
[No Abstract] [Full Text] [Related]
59. Response to Pearl's comments on principal stratification.
Egleston BL
Int J Biostat; 2011; 7(1):24. PubMed ID: 21686084
[TBL] [Abstract][Full Text] [Related]
60. Epidemiologic evidence and causal inference.
Weed DL
Hematol Oncol Clin North Am; 2000 Aug; 14(4):797-807, viii. PubMed ID: 10949774
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
